Issues and concerns related to the EU’s competitiveness in this sector, in particular regarding European legislation, U.S. tariffs on pharmaceuticals, and intellectual property. (Lobbyradar DE, 2026)
Daten unter CC-BY-SA 4.0; Quellen siehe Detailseite.